Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 15/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718183 | 1.00 | PIK3CD (0.58) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL2720104 | 0.91 | PIK3CD (0.68) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL3776243 | 0.91 | PIK3CD (0.68) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL2720600 | 0.88 | PIK3CD (0.65) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL2717204 | 0.85 | PIK3CD (0.53) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL3784291 | 0.85 | PIK3CD (0.53) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL3785526 | 0.84 | PIK3CD (0.54) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL3785529 | 0.84 | PIK3CD (0.54) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL2718187 | 0.82 | PIK3CD (0.48) | PIK3CDPIK3CBPIK3CGPIK3CAPDE10A | |
| SCHEMBL2731781 | 0.81 | PIK3CD (0.88) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| EP-2445900-B1 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | AMGEN INC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 15/4885PIK3CB 35/4885PIK3CG 53/4885 |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885PIK3CB 35/4885PIK3CG 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.